The FDA has announced its timeline for completing a safety review of the abortion pill mifepristone, stating it will finish by March. This announcement comes in the wake of a federal judge’s order in Louisiana, which demanded an update on the review process amid a lawsuit challenging the medication’s mail delivery provision.
According to a court filing from the Justice Department, the FDA’s examination will focus on comparing the safety profile of mifepristone to that of surgical abortions performed within the first 10 weeks of gestation. The agency plans to assess side effects experienced by approximately 100,000 women who have taken the drug.
Results from this review are anticipated in mid-December, after which the FDA will analyze the data and prepare a final report, which is expected to be released by March. Mifepristone has been widely used since its approval in 2000, with numerous peer-reviewed studies affirming its safety and efficacy.
In a significant shift, the FDA had lifted the in-person dispensing requirement for mifepristone in 2021, a decision finalized in 2023. The agency plans to reconsider this policy based on the new findings, potentially taking into account perspectives from patients, healthcare providers, and pharmacists, as well as additional studies not previously evaluated.
Notably, the timing of the FDA’s review aligns with the upcoming midterm elections on November 3, where abortion access is a key issue for voters. The ongoing legal situation includes a lawsuit from Louisiana, initiated on behalf of a woman who claimed her boyfriend coerced her into taking abortion pills.
In May, a federal appeals court had reinstated a requirement for mifepristone to be dispensed in person, but the Supreme Court intervened, temporarily blocking this ruling while the case continues. This legal backdrop underscores the contentious debate surrounding abortion access in the U.S., particularly following the Supreme Court’s decision to overturn Roe v. Wade in 2022.
The FDA’s review was prompted by claims from a conservative think tank alleging a higher incidence of severe complications associated with mifepristone than reported by federal health agencies. However, reproductive health researchers have dismissed these claims as unsubstantiated and lacking scientific rigor, highlighting that serious adverse reactions to the drug occur in less than 0.5% of users.
Under the Trump administration, there has been pressure from Republican lawmakers to tighten regulations around mifepristone, with Health Secretary Robert F. Kennedy Jr. commissioning this safety review. The FDA, currently without a permanent commissioner, faces scrutiny on how it will interpret the new data, especially with Dr. Heidi Overton, a known opponent of abortion rights, as Trump’s nominee to lead the agency.
As the situation develops, the FDA’s forthcoming decisions will likely play a crucial role in shaping the landscape of abortion access in the U.S. amidst ongoing political and legal challenges.
Photo credit: Shuran Huang
